<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="http://www.accessdata.fda.gov/spl/stylesheet/spl.xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 http://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="60d516c6-231e-43c1-bdd8-7fab0e116f0a"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>These highlights do not include all the information needed to use KETOROLAC TROMETHAMINE OPHTHALMIC SOLUTION, 0.4% safely and effectively. See full prescribing information for KETOROLAC TROMETHAMINE OPHTHALMIC SOLUTION, 0.4%.<br/>KETOROLAC TROMETHAMINE ophthalmic solution, 0.4%, for topical ophthalmic use <br/>Initial U.S. Approval: 1991
</title>
   <effectiveTime value="20160531"/>
   <setId root="416e6f6e-796d-6f75-7357-617348657265"/>
   <versionNumber value="3"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="062649876" root="1.3.6.1.4.1.519.1"/>
            <name>Akorn Inc.</name>
            <assignedEntity>
               <assignedOrganization>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="603980319" root="1.3.6.1.4.1.519.1"/>
                        <name>Akorn Inc.</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C43360" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="17478-208" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="17478-208" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C73606" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="REPACK"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="17478-208" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section ID="dcl-dpl">
               <id root="c1b8fd76-6618-464c-b193-6065152920f2"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL PRODUCT DATA ELEMENTS SECTION"/>
               <effectiveTime value="20090801"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="17478-208" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Ketorolac Tromethamine</name>
                        <formCode code="C42986" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="SOLUTION"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Ketorolac Tromethamine</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator value="4" unit="mg"/>
                              <denominator value="1" unit="mL"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="4EVE5946BQ" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>ketorolac tromethamine</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="YZI5105V0L" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>ketorolac</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="F5UM2KM3W7" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>benzalkonium chloride</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="7FLD91C86K" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>edetate disodium</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="9T1C662FKS" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>octoxynol-40</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="451W47IQ8X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>sodium chloride</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="QTT17582CB" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>hydrochloric acid</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="55X04QC32I" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>sodium hydroxide</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>water</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="5" unit="mL"/>
                              <denominator value="1" unit="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43171" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE, DROPPER"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="1" unit="1"/>
                                    <denominator value="1" unit="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="17478-208-10" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20091105"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV" displayName="Type 0: Not a Combination Product"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20091105"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <approval>
                           <id root="2.16.840.1.113883.3.150" extension="ANDA078399"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38287" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="OPHTHALMIC"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="s1">
               <id root="80234a41-7b9e-4aa4-84a0-b33ecc1286e2"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE
</title>
               <text>
                  <paragraph>Ketorolac tromethamine ophthalmic solution is indicated for the reduction of ocular pain and burning/stinging following corneal refractive surgery.
</paragraph>
               </text>
               <effectiveTime value="20160531"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Ketorolac tromethamine ophthalmic solution is a nonsteroidal, anti-inflammatory drug (NSAID) indicated for the reduction of ocular pain and burning/stinging following corneal refractive surgery. (<linkHtml href="#s1">1</linkHtml>)
</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="s2">
               <id root="f0914cc4-806f-4f19-b01a-2190e99a01b8"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION
</title>
               <effectiveTime value="20160531"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>One drop of ketorolac tromethamine ophthalmic solution should be applied in the operated eye 4 times per day as needed for pain and burning/stinging for up to 4 days following corneal refractive surgery. (<linkHtml href="#s3">2.1</linkHtml>)
</paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="s3">
                     <id root="828cd7f1-bee0-421e-8171-5a4da15b6af8"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.1 Recommended Dosing
</title>
                     <text>
                        <paragraph>The recommended dose of ketorolac tromethamine ophthalmic solution is one drop four times a day in the operated eye as needed for pain and burning/stinging for up to 4 days following corneal refractive surgery.
</paragraph>
                     </text>
                     <effectiveTime value="20160531"/>
                  </section>
               </component>
               <component>
                  <section ID="s4">
                     <id root="b28bfe92-56ca-44b7-bea5-fc8b7b09a576"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.2 Use With Other Topical Ophthalmic Medications
</title>
                     <text>
                        <paragraph>Ketorolac tromethamine ophthalmic solution has been safely administered in conjunction with other topical ophthalmic medications such as alpha-agonists, antibiotics, beta-blockers, carbonic anhydrase inhibitors, cycloplegics, and mydriatics. Drops should be administered at least 5 minutes apart.
</paragraph>
                     </text>
                     <effectiveTime value="20160531"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s5">
               <id root="c9ae27ca-2c48-47b9-852c-a67bb13920aa"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS
</title>
               <text>
                  <paragraph>10 mL size bottle filled with 5 mL of ketorolac tromethamine ophthalmic solution, 0.4% (4 mg/mL).
</paragraph>
               </text>
               <effectiveTime value="20160531"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Ophthalmic solution containing 4 mg/mL ketorolac tromethamine in a 10 mL size bottle filled with 5 mL of solution. (<linkHtml href="#s5">3</linkHtml>)
</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="s6">
               <id root="bde868bc-dec7-400b-ac74-d16bab1ee21a"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS
</title>
               <text>
                  <paragraph>Ketorolac tromethamine ophthalmic solution is contraindicated in patients with previously demonstrated hypersensitivity to any of the ingredients in the formulation.
</paragraph>
               </text>
               <effectiveTime value="20160531"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Hypersensitivity to any component of this product. (<linkHtml href="#s6">4</linkHtml>)
</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="s7">
               <id root="4eafc342-6b37-4381-8a38-43306b1cca35"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS
</title>
               <effectiveTime value="20160531"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Delayed healing (<linkHtml href="#s8">5.1</linkHtml>)
</paragraph>
                        <paragraph>Cross-sensitivity or hypersensitivity (<linkHtml href="#s9">5.2</linkHtml>)
</paragraph>
                        <paragraph>Increased bleeding time due to interference with thrombocyte aggregation (<linkHtml href="#s10">5.3</linkHtml>)
</paragraph>
                        <paragraph>Corneal effects including keratitis (<linkHtml href="#s11">5.4</linkHtml>)
</paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="s8">
                     <id root="1beb585f-0827-44e0-ac98-ca1e410c4b9b"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.1 Delayed Healing
</title>
                     <text>
                        <paragraph>Topical nonsteroidal anti-inflammatory drugs (NSAIDs) may slow or delay healing. Topical corticosteroids are also known to slow or delay healing. Concomitant use of topical NSAIDs and topical steroids may increase the potential for healing problems.
</paragraph>
                     </text>
                     <effectiveTime value="20160531"/>
                  </section>
               </component>
               <component>
                  <section ID="s9">
                     <id root="d0bac86c-7f96-4063-be2b-18212817f497"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.2 Cross-Sensitivity or Hypersensitivity
</title>
                     <text>
                        <paragraph>There is the potential for cross-sensitivity to acetylsalicylic acid, phenylacetic acid derivatives, and other NSAIDs. There have been reports of bronchospasm or exacerbation of asthma associated with the use of ketorolac tromethamine ophthalmic solution in patients who have either a known hypersensitivity to aspirin/non-steroidal anti-inflammatory drugs or a past medical history of asthma. Therefore, caution should be used when treating individuals who have previously exhibited sensitivities to these drugs.
</paragraph>
                     </text>
                     <effectiveTime value="20160531"/>
                  </section>
               </component>
               <component>
                  <section ID="s10">
                     <id root="871771c2-38fa-44e8-b9aa-98f890eb0a26"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.3 Increased Bleeding Time
</title>
                     <text>
                        <paragraph>With some NSAIDs, there exists the potential for increased bleeding time due to interference with thrombocyte aggregation. There have been reports that ocularly applied nonsteroidal anti-inflammatory drugs may cause increased bleeding of ocular tissues (including hyphemas) in conjunction with ocular surgery.
</paragraph>
                        <paragraph>It is recommended that ketorolac tromethamine ophthalmic solution be used with caution in patients with known bleeding tendencies or who are receiving other medications, which may prolong bleeding time.
</paragraph>
                     </text>
                     <effectiveTime value="20160531"/>
                  </section>
               </component>
               <component>
                  <section ID="s11">
                     <id root="0a0990cc-7990-4902-b8b7-f8b2d0a52a01"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.4 Corneal Effects
</title>
                     <text>
                        <paragraph>Use of topical NSAIDs may result in keratitis. In some susceptible patients, continued use of topical NSAIDs may result in epithelial breakdown, corneal thinning, corneal erosion, corneal ulceration, or corneal perforation. These events may be sight threatening. Patients with evidence of corneal epithelial breakdown should immediately discontinue use of topical NSAIDs and should be closely monitored for corneal health.
</paragraph>
                        <paragraph>Postmarketing experience with topical NSAIDs suggests that patients with complicated ocular surgeries, corneal denervation, corneal epithelial defects, diabetes mellitus, ocular surface diseases (e.g., dry eye syndrome), rheumatoid arthritis, or repeat ocular surgeries within a short period of time may be at increased risk for corneal adverse events which may become sight threatening. Topical NSAIDs should be used with caution in these patients.
</paragraph>
                        <paragraph>Postmarketing experience with topical NSAIDs also suggests that use more than 1 day prior to surgery or use beyond 14 days post-surgery may increase patient risk for the occurrence and severity of corneal adverse events.
</paragraph>
                     </text>
                     <effectiveTime value="20160531"/>
                  </section>
               </component>
               <component>
                  <section ID="s12">
                     <id root="ab341ff3-542f-428b-8e89-54085e7bac56"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.5 Contact Lens Wear
</title>
                     <text>
                        <paragraph>Ketorolac tromethamine ophthalmic solution should not be administered while wearing contact lenses.
</paragraph>
                     </text>
                     <effectiveTime value="20160531"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s13">
               <id root="57888874-d256-4e93-b6b3-53867415e8f0"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS
</title>
               <text>
                  <paragraph>The following serious adverse reactions are described elsewhere in the labeling:
</paragraph>
                  <paragraph>Delayed Healing [<content styleCode="italics">see Warnings and Precautions (<linkHtml href="#s8">5.1</linkHtml>)</content>]
</paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>Cross-Sensitivity or Hypersensitivity [<content styleCode="italics">see Warnings and Precautions (<linkHtml href="#s9">5.2</linkHtml>)</content>]
</item>
                     <item>Increased Bleeding Time [<content styleCode="italics">see Warnings and Precautions (<linkHtml href="#s10">5.3</linkHtml>)</content>]
</item>
                     <item>Corneal Effects [<content styleCode="italics">see Warnings and Precautions (<linkHtml href="#s11">5.4</linkHtml>)</content>]
</item>
                  </list>
               </text>
               <effectiveTime value="20160531"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>The most common adverse reactions occurring in 1% to 5% of patients included conjunctival hyperemia, corneal infiltrates, headache, ocular edema and ocular pain. (<linkHtml href="#s14">6.1</linkHtml>)
</paragraph>
                        <paragraph>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact Akorn, Inc. at 1-800-932-5676 or the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="s14">
                     <id root="737e7ff1-363d-40d9-99ca-4454f726696a"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>6.1 Clinical Studies Experience
</title>
                     <text>
                        <paragraph>Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice.
</paragraph>
                        <paragraph>The most frequently reported adverse reactions for ketorolac tromethamine ophthalmic solution occurring in approximately 1% to 5% of the overall study population were conjunctival hyperemia, corneal infiltrates, headache, ocular edema, and ocular pain.
</paragraph>
                        <paragraph>The most frequent adverse reactions reported with the use of ketorolac tromethamine ophthalmic solutions have been transient stinging and burning on instillation. These reactions were reported by up to 40% of patients participating in clinical trials.
</paragraph>
                        <paragraph>Other adverse reactions occurring approximately in 1% to 10% of the time during treatment with other ketorolac tromethamine ophthalmic solutions included allergic reactions, corneal edema, iritis, ocular inflammation, ocular irritation, superficial keratitis, and superficial ocular infections.
</paragraph>
                        <paragraph>Other adverse reactions reported rarely with the use of ketorolac tromethamine ophthalmic solutions included: corneal ulcer, eye dryness, and visual disturbance (blurry vision).
</paragraph>
                     </text>
                     <effectiveTime value="20160531"/>
                  </section>
               </component>
               <component>
                  <section ID="s15">
                     <id root="392fdc51-8e7e-47d2-bfb3-1faafb2c6e12"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>6.2 Postmarketing Experience
</title>
                     <text>
                        <paragraph>The following adverse reactions have been identified during postmarketing use of ketorolac tromethamine ophthalmic solutions in clinical practice. Because they are reported voluntarily from a population of unknown size, estimates of frequency cannot be made. The reactions, which have been chosen for inclusion due to either their seriousness, frequency of reporting, possible causal connection to topical ketorolac tromethamine ophthalmic solutions or a combination of these factors, include bronchospasm or exacerbation of asthma, corneal erosion, corneal perforation, corneal thinning and corneal melt, and epithelial breakdown [<content styleCode="italics">see Warnings and Precautions (<linkHtml href="#s9">5.2</linkHtml>, <linkHtml href="#s11">5.4</linkHtml>)</content>].
</paragraph>
                     </text>
                     <effectiveTime value="20160531"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s16">
               <id root="43bb0fb9-8322-4c3e-8515-825d45b47639"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS
</title>
               <effectiveTime value="20160531"/>
               <component>
                  <section ID="s17">
                     <id root="30ed21c9-3fa1-4737-aaa1-d71440adc132"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1 Pregnancy
</title>
                     <effectiveTime value="20160531"/>
                     <component>
                        <section ID="s18">
                           <id root="8ac97985-73d5-42e3-be15-9cd0c609a02d"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Risk Summary</content>
                              </paragraph>
                              <paragraph>There are no adequate or well-controlled studies with ketorolac tromethamine ophthalmic solution in pregnant women. No evidence of teratogenicity has been observed in rats or rabbits with ketorolac tromethamine ophthalmic solution at clinically relevant doses.
</paragraph>
                           </text>
                           <effectiveTime value="20160531"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="s19">
                     <id root="cf808c65-dc95-4fbe-99cf-bdbfd4daa361"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>8.2 Lactation
</title>
                     <effectiveTime value="20160531"/>
                     <component>
                        <section ID="s20">
                           <id root="f0caa24c-437b-4fec-b2d6-3d271240a906"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Risk Summary</content>
                              </paragraph>
                              <paragraph>It is not known whether ketorolac when given topically is present in human milk. Because many drugs are excreted in human milk, caution should be exercised when ketorolac tromethamine ophthalmic solution is administered to a nursing woman.
</paragraph>
                           </text>
                           <effectiveTime value="20160531"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="s21">
                     <id root="2daa5d3e-0f4a-419a-a2c9-17b32dcbf4b6"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4 Pediatric Use
</title>
                     <text>
                        <paragraph>Safety and effectiveness of ketorolac tromethamine in pediatric patients below the age of 3 have not been established.
</paragraph>
                     </text>
                     <effectiveTime value="20160531"/>
                  </section>
               </component>
               <component>
                  <section ID="s22">
                     <id root="57f7f7da-7845-46e8-bd54-e529d60bb7a3"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5 Geriatric Use
</title>
                     <text>
                        <paragraph>No overall differences in safety or effectiveness have been observed between elderly and other adult patients.
</paragraph>
                     </text>
                     <effectiveTime value="20160531"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s23">
               <id root="6506006e-f6c8-407f-b047-db7f03bd121c"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION
</title>
               <text>
                  <paragraph>Ketorolac tromethamine ophthalmic solution, 0.4% is a member of the pyrrolo-pyrrole group of nonsteroidal anti-inflammatory drugs (NSAIDs) for ophthalmic use. Its chemical name is (±)-5-Benzoyl-2,3-dihydro-1<content styleCode="italics">H</content>-pyrrolizine-1-carboxylic acid, compound with 2-amino-2-(hydroxymethyl)-1,3-propanediol (1:1), and its molecular weight is 376.40. Its molecular formula is C<sub>19</sub>H<sub>24</sub>N<sub>2</sub>O<sub>6</sub> and it has the following structure:
</paragraph>
                  <renderMultiMedia ID="f01" referencedObject="mm01"/>
                  <paragraph>Ketorolac tromethamine ophthalmic solution is supplied as a sterile isotonic aqueous 0.4% solution, with a pH of approximately 7.4. Ketorolac tromethamine ophthalmic solution contains a racemic mixture of R(+) and S-(-)-ketorolac tromethamine. Ketorolac tromethamine may exist in three crystal forms. All forms are equally soluble in water. The pKa of ketorolac is 3.5. This white to off-white crystalline substance discolors on prolonged exposure to light. The osmolality of ketorolac tromethamine ophthalmic solution is 290 mOsmol/kg.
</paragraph>
                  <paragraph>Each mL of ketorolac tromethamine ophthalmic solution, 0.4% contains: <content styleCode="bold">Active:</content> ketorolac tromethamine 0.4%. <content styleCode="bold">Inactives:</content> edetate disodium 0.015%; octoxynol 40; purified water; sodium chloride; and hydrochloric acid and/or sodium hydroxide to adjust pH. <content styleCode="bold">Preservative:</content> benzalkonium chloride 0.006%.
</paragraph>
               </text>
               <effectiveTime value="20160531"/>
               <component>
                  <observationMedia ID="mm01">
                     <text>Structural Formula
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="ket01-0001-01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="s24">
               <id root="f1c5c29e-4a68-47d5-9b88-5df02abbd6ae"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY
</title>
               <effectiveTime value="20160531"/>
               <component>
                  <section ID="s25">
                     <id root="5005c286-9ed1-49ff-b41e-c139261dc1b7"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1  Mechanism of Action
</title>
                     <text>
                        <paragraph>Ketorolac tromethamine is a nonsteroidal anti-inflammatory drug which, when administered systemically, has demonstrated analgesic, anti-inflammatory, and anti-pyretic activity. The mechanism of its action is thought to be due to its ability to inhibit prostaglandin biosynthesis.
</paragraph>
                     </text>
                     <effectiveTime value="20160531"/>
                  </section>
               </component>
               <component>
                  <section ID="s26">
                     <id root="3270587d-f304-4bad-9702-797ac9d8e5ba"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3  Pharmacokinetics
</title>
                     <text>
                        <paragraph>One drop of 0.5% ketorolac tromethamine ophthalmic solution was instilled into one eye and one drop of vehicle into the other eye TID in 26 healthy subjects. Five of 26 subjects had detectable concentrations of ketorolac in their plasma (range 11 to 23 ng/mL) at day 10 during topical ocular treatment.
</paragraph>
                        <paragraph>Two drops of 0.5% ketorolac tromethamine ophthalmic solution instilled into the eyes of patients 12 hours and 1 hour prior to cataract extraction achieved a mean ketorolac concentration of 95 ng/mL in the aqueous humor of 8 of 9 eyes tested (range 40 to 170 ng/mL).
</paragraph>
                     </text>
                     <effectiveTime value="20160531"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s27">
               <id root="278a36be-fab6-4a94-8f48-4cdb95f7f037"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
               <title>14 CLINICAL STUDIES
</title>
               <text>
                  <paragraph>In two double-masked, multi-centered, parallel-group studies, 313 patients who had undergone photorefractive keratectomy received ketorolac tromethamine ophthalmic solution or its vehicle QID for up to 4 days. Significant differences favored ketorolac tromethamine ophthalmic solution for the reduction of ocular pain and burning/stinging following photorefractive keratectomy surgery.
</paragraph>
                  <paragraph>Results from clinical studies indicate that ketorolac tromethamine has no significant effect upon intraocular pressure.
</paragraph>
                  <paragraph>The safety and effectiveness of ketorolac tromethamine ophthalmic solution in post-cataract surgery patients has not been established.
</paragraph>
               </text>
               <effectiveTime value="20160531"/>
            </section>
         </component>
         <component>
            <section ID="s28">
               <id root="8383c7fb-1a33-4ffd-abd7-7f6f9ffa1fcf"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING
</title>
               <text>
                  <paragraph>Ketorolac tromethamine ophthalmic solution, 0.4% is supplied sterile, in a white LDPE boston round bottle with a LDPE natural-colored dropper tip and a gray short skirt cap as follows:
</paragraph>
                  <paragraph>5 mL in 10 mL bottle - NDC 17478-208-10
</paragraph>
               </text>
               <effectiveTime value="20160531"/>
               <component>
                  <section ID="s29">
                     <id root="cadb05ea-0027-4063-a0e5-407d4c90cfb1"/>
                     <code code="44425-7" codeSystem="2.16.840.1.113883.6.1" displayName="STORAGE AND HANDLING SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="bold">Storage:</content> Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature].
</paragraph>
                        <paragraph>Protect from light.
</paragraph>
                     </text>
                     <effectiveTime value="20160531"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s30">
               <id root="384df3e5-68c0-4588-adb7-3feb459a5b3c"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17 PATIENT COUNSELING INFORMATION
</title>
               <effectiveTime value="20160531"/>
               <component>
                  <section ID="s31">
                     <id root="51122fb4-be76-4c02-9d71-f2f1d0d62042"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="bold">Slow or Delayed Healing</content>
                        </paragraph>
                        <paragraph>Inform patients of the possibility that slow or delayed healing may occur while using nonsteroidal anti-inflammatory drugs (NSAIDs).
</paragraph>
                     </text>
                     <effectiveTime value="20160531"/>
                  </section>
               </component>
               <component>
                  <section ID="s32">
                     <id root="af2fdb7f-3395-435b-8f13-e531f515c221"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="bold">Avoiding Contamination of the Product</content>
                        </paragraph>
                        <paragraph>Instruct patients to avoid allowing the tip of the bottle to contact the eye or surrounding structures because this could cause the tip to become contaminated by common bacteria known to cause ocular infections. Serious damage to the eye and subsequent loss of vision may result from using contaminated solutions. Also, to avoid the potential for cross-contamination, the patient should be advised to use one bottle for each eye following bilateral ocular surgery. The use of the same bottle of topical eye drops for both eyes following bilateral ocular surgery is not recommended.
</paragraph>
                     </text>
                     <effectiveTime value="20160531"/>
                  </section>
               </component>
               <component>
                  <section ID="s33">
                     <id root="a3ccd26f-ca17-4c77-8a58-4e1da8584080"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="bold">Contact Lens Wear</content>
                        </paragraph>
                        <paragraph>Advise patients that ketorolac tromethamine ophthalmic solution should not be administered while wearing contact lenses.
</paragraph>
                     </text>
                     <effectiveTime value="20160531"/>
                  </section>
               </component>
               <component>
                  <section ID="s34">
                     <id root="da5c8262-a3cc-476a-af47-47384b8fd42d"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="bold">Intercurrent Ocular Conditions</content>
                        </paragraph>
                        <paragraph>Advise patients that if they develop an intercurrent ocular condition (e.g., trauma or infection) or have ocular surgery, they should immediately seek their physician's advice concerning the continued use of ketorolac tromethamine ophthalmic solution.
</paragraph>
                     </text>
                     <effectiveTime value="20160531"/>
                  </section>
               </component>
               <component>
                  <section ID="s35">
                     <id root="6ea216d5-7128-4133-b52d-f50b49f450db"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="bold">Concomitant Topical Ocular Therapy</content>
                        </paragraph>
                        <paragraph>Advise patients that if more than one topical ophthalmic medication is being used, the medicines should be administered at least 5 minutes apart.
</paragraph>
                        <paragraph>
                           <content styleCode="bold">AKORN<br/>
                           </content>Manufactured by: <br/>
                           <content styleCode="bold">Akorn, Inc.<br/>
                           </content>Lake Forest, IL  60045
</paragraph>
                        <paragraph>KRA0N
</paragraph>
                        <paragraph>Rev. 05/16
</paragraph>
                     </text>
                     <effectiveTime value="20160531"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s36">
               <id root="3fd04803-888b-4736-936b-2db5e9fb6cd5"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <text>
                  <paragraph>Principal Display Panel Text for Container Label:
</paragraph>
                  <paragraph>NDC 17478-208-10
</paragraph>
                  <paragraph>Ketorolac
</paragraph>
                  <paragraph>Tromethamine
</paragraph>
                  <paragraph>Ophthalmic Solution
</paragraph>
                  <paragraph>0.4%
</paragraph>
                  <paragraph>Rx only 5 mL
</paragraph>
                  <paragraph>Akorn Logo
</paragraph>
                  <renderMultiMedia ID="f02" referencedObject="mm02"/>
               </text>
               <effectiveTime value="20141106"/>
               <component>
                  <observationMedia ID="mm02">
                     <text>Principal Display Panel Text for Container Label
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="ket01-0001-02.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="s37">
               <id root="7abfabb2-6dc9-45c8-bf65-bb8ba1c85591"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <text>
                  <paragraph>Principal Display Panel Text for Carton Label:
</paragraph>
                  <paragraph>NDC 17478-208-10
</paragraph>
                  <paragraph>Ketorolac
</paragraph>
                  <paragraph>Tromethamine
</paragraph>
                  <paragraph>Ophthalmic
</paragraph>
                  <paragraph>Solution
</paragraph>
                  <paragraph>0.4%
</paragraph>
                  <paragraph>FOR TOPICAL OPHTHALMIC
</paragraph>
                  <paragraph>USE ONLY
</paragraph>
                  <paragraph>5 mL
</paragraph>
                  <paragraph>Rx only Akorn Logo
</paragraph>
                  <renderMultiMedia ID="f03" referencedObject="mm03"/>
               </text>
               <effectiveTime value="20141106"/>
               <component>
                  <observationMedia ID="mm03">
                     <text>Principal Display Panel Text for Carton Label
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="ket01-0001-03.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>